CDT Equity Inc. (CDT) is a Naples, Florida-based, data-driven biopharmaceutical developer — formerly Conduit Pharmaceuticals — whose pipeline includes the glucokinase activator AZD1656 in Phase II testing for autoimmune conditions, along with earlier-stage assets and a 22.7% stake in Sarborg Limited, its principal holding. The company employs a handful of staff and carries a market value well below $1 million.
Shares last changed hands at $0.2912, a decline of 15.10% from the previous session's close of $0.343. The direction was decisively lower, and the stock printed a new 52-week low during the session. The proximate news was a press release noting Sarborg's $12.5 million sale of its cryptocurrency trading agent to Ebers Tech, alongside confirmation that CDT itself has no Bitcoin treasury reserve strategy. That disclosure was credible and timely but structurally indirect, and it arrived into a market already focused on dilution.
The Sarborg announcement is meaningful in absolute terms but limited in benefit to CDT shareholders. Consideration of $12.5 million dwarfs the parent's sub-$1 million market capitalization, yet the cash is received at the Sarborg level, where CDT holds a minority position accounted for under the equity method. What CDT retains is a perpetual, royalty-free licence to use the agent inside its own treasury operations. Investors appear to have read that as the disposal of a headline asset without a distributable windfall, while the explicit denial of any Bitcoin treasury strategy removed a speculative narrative that has lifted other micro-caps this year.
The larger driver is capital structure. On Nov. 12, stockholders approved share issuance under Nasdaq Listing Rule 5635 tied to senior secured convertible notes and warrants issued to J.J. Astor & Co., and authorized reverse splits at ratios from 1-for-2 to 1-for-100. That followed a 1-for-25 split in late September and a 1-for-20 split effective Nov. 6, which cut the share count from roughly 20.36 million to about 1.02 million. Convertible financing of this type converts at floating discounts, so each new tranche adds supply faster than demand absorbs it. The company's own largest shareholder has publicly flagged dependence on continuous equity issuance and the going-concern qualification in its accounts — a critique that keeps sellers in control regardless of operational headlines.
Early in November, former chief executive Andrew Regan, writing through Corvus Capital, proposed acquiring all outstanding shares at $2.00 — a 96.3% premium to the Nov. 4 close of $1.018. Shares jumped 54.85% on Nov. 6 but fell 35.9% and 33.2% in the following two sessions. The proposal is expressly non-binding, no definitive agreement has been announced, and the stock now trades at roughly one-seventh of the indicated price. With the arbitrage spread this wide, the market is pricing significant doubt that a transaction completes on those terms.
Turnover in recent sessions has run between roughly 100,000 and 300,000 shares, a fraction of the high-six-figure to multi-million-share averages recorded earlier in 2026. There was no evidence of a volume surge accompanying today's decline, which is consistent with thin liquidity amplifying price movement rather than an institutional exit. The sell-off was also idiosyncratic: no peer or sector-wide catalyst explains a move of this size, and the wider biotechnology complex showed no comparable dislocation. Technically, the stock sits beneath every meaningful moving average and broke below the $0.3215 November low, leaving no established support beneath current levels.
The score runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news and an extreme, rare price move. The verified news here is narrow: a $12.5 million asset sale at a minority-owned affiliate, with no proceeds routed to CDT and no change to its own liquidity. Judged against the company's size it is a modest, third-party development rather than a balance-sheet event.
The price move was equally unremarkable by this stock's standards. Today's 15.10% decline is roughly 1.1 times the 13.8% average absolute daily move of the past 60 sessions, and 17 of those sessions produced moves of similar or greater magnitude. Weak news and an ordinary move combine to 13 out of 100.
Estimated earnings are due around Nov. 27, and the report will be scrutinized less for pipeline progress than for cash, burn and the pace of note conversions. The board's formal position on the Corvus proposal is the other scheduled unknown, alongside any at-the-market sales or new convertible tranches disclosed in filings. Operationally, investors will watch the tapinarof skin studies with QIMA Life Sciences and any licensing progress on the AZD assets. Sector developments in autoimmune and dermatology assets offer optionality, but with going-concern language in the accounts and a share count that has repeatedly reset, financing risk remains the dominant uncertainty.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and traded symbols, letting users compare rule-based approaches against a name as volatile as CDT. Reviewing the current leaderboard is a practical way to see which strategies are working in this market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDT declined for three days, in 290 of 301 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CDT entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.010) is normal, around the industry mean (3.592). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. CDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology